Cargando…

Tumor Necrosis Factor-α Antagonism Improves Vasodilation During Hyperinsulinemia in Metabolic Syndrome

OBJECTIVE—Obesity is associated with chronic inflammation due to overproduction of proinflammatory cytokines, including tumor necrosis factor (TNF)-α. We assessed the effects of TNF-α neutralization by infliximab on vascular reactivity during hyperinsulinemia in obesity-related metabolic syndrome. R...

Descripción completa

Detalles Bibliográficos
Autores principales: Tesauro, Manfredi, Schinzari, Francesca, Rovella, Valentina, Melina, Domenico, Mores, Nadia, Barini, Angela, Mettimano, Marco, Lauro, Davide, Iantorno, Micaela, Quon, Michael J., Cardillo, Carmine
Formato: Texto
Lenguaje:English
Publicado: American Diabetes Association 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2453644/
https://www.ncbi.nlm.nih.gov/pubmed/18390795
http://dx.doi.org/10.2337/dc08-0219
_version_ 1782157384570896384
author Tesauro, Manfredi
Schinzari, Francesca
Rovella, Valentina
Melina, Domenico
Mores, Nadia
Barini, Angela
Mettimano, Marco
Lauro, Davide
Iantorno, Micaela
Quon, Michael J.
Cardillo, Carmine
author_facet Tesauro, Manfredi
Schinzari, Francesca
Rovella, Valentina
Melina, Domenico
Mores, Nadia
Barini, Angela
Mettimano, Marco
Lauro, Davide
Iantorno, Micaela
Quon, Michael J.
Cardillo, Carmine
author_sort Tesauro, Manfredi
collection PubMed
description OBJECTIVE—Obesity is associated with chronic inflammation due to overproduction of proinflammatory cytokines, including tumor necrosis factor (TNF)-α. We assessed the effects of TNF-α neutralization by infliximab on vascular reactivity during hyperinsulinemia in obesity-related metabolic syndrome. RESEARCH DESIGN AND METHODS—Vascular responses to intra-arterial infusion of acetylcholine (ACh) and sodium nitroprusside (SNP) were assessed in patients with metabolic syndrome, before and after administration of infliximab. RESULTS—Patients had blunted vasodilator responses to ACh and SNP during hyperinsulinemia compared with control subjects; a potentiation of the responsiveness to both ACh and SNP, however, was observed in patients following infliximab. The antioxidant vitamin C improved the vasodilator response to ACh in patients with metabolic syndrome, but its effect was not further enhanced by concurrent administration of infliximab. CONCLUSIONS—TNF-α neutralization ameliorates vascular reactivity in metabolic syndrome during hyperinsulinemia, likely in relation to decreased oxidative stress, thereby suggesting an involvement of inflammatory cytokines in vascular dysfunction of these patients.
format Text
id pubmed-2453644
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher American Diabetes Association
record_format MEDLINE/PubMed
spelling pubmed-24536442009-07-01 Tumor Necrosis Factor-α Antagonism Improves Vasodilation During Hyperinsulinemia in Metabolic Syndrome Tesauro, Manfredi Schinzari, Francesca Rovella, Valentina Melina, Domenico Mores, Nadia Barini, Angela Mettimano, Marco Lauro, Davide Iantorno, Micaela Quon, Michael J. Cardillo, Carmine Diabetes Care Cardiovascular and Metabolic Risk OBJECTIVE—Obesity is associated with chronic inflammation due to overproduction of proinflammatory cytokines, including tumor necrosis factor (TNF)-α. We assessed the effects of TNF-α neutralization by infliximab on vascular reactivity during hyperinsulinemia in obesity-related metabolic syndrome. RESEARCH DESIGN AND METHODS—Vascular responses to intra-arterial infusion of acetylcholine (ACh) and sodium nitroprusside (SNP) were assessed in patients with metabolic syndrome, before and after administration of infliximab. RESULTS—Patients had blunted vasodilator responses to ACh and SNP during hyperinsulinemia compared with control subjects; a potentiation of the responsiveness to both ACh and SNP, however, was observed in patients following infliximab. The antioxidant vitamin C improved the vasodilator response to ACh in patients with metabolic syndrome, but its effect was not further enhanced by concurrent administration of infliximab. CONCLUSIONS—TNF-α neutralization ameliorates vascular reactivity in metabolic syndrome during hyperinsulinemia, likely in relation to decreased oxidative stress, thereby suggesting an involvement of inflammatory cytokines in vascular dysfunction of these patients. American Diabetes Association 2008-07 /pmc/articles/PMC2453644/ /pubmed/18390795 http://dx.doi.org/10.2337/dc08-0219 Text en Copyright © 2008, American Diabetes Association Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.
spellingShingle Cardiovascular and Metabolic Risk
Tesauro, Manfredi
Schinzari, Francesca
Rovella, Valentina
Melina, Domenico
Mores, Nadia
Barini, Angela
Mettimano, Marco
Lauro, Davide
Iantorno, Micaela
Quon, Michael J.
Cardillo, Carmine
Tumor Necrosis Factor-α Antagonism Improves Vasodilation During Hyperinsulinemia in Metabolic Syndrome
title Tumor Necrosis Factor-α Antagonism Improves Vasodilation During Hyperinsulinemia in Metabolic Syndrome
title_full Tumor Necrosis Factor-α Antagonism Improves Vasodilation During Hyperinsulinemia in Metabolic Syndrome
title_fullStr Tumor Necrosis Factor-α Antagonism Improves Vasodilation During Hyperinsulinemia in Metabolic Syndrome
title_full_unstemmed Tumor Necrosis Factor-α Antagonism Improves Vasodilation During Hyperinsulinemia in Metabolic Syndrome
title_short Tumor Necrosis Factor-α Antagonism Improves Vasodilation During Hyperinsulinemia in Metabolic Syndrome
title_sort tumor necrosis factor-α antagonism improves vasodilation during hyperinsulinemia in metabolic syndrome
topic Cardiovascular and Metabolic Risk
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2453644/
https://www.ncbi.nlm.nih.gov/pubmed/18390795
http://dx.doi.org/10.2337/dc08-0219
work_keys_str_mv AT tesauromanfredi tumornecrosisfactoraantagonismimprovesvasodilationduringhyperinsulinemiainmetabolicsyndrome
AT schinzarifrancesca tumornecrosisfactoraantagonismimprovesvasodilationduringhyperinsulinemiainmetabolicsyndrome
AT rovellavalentina tumornecrosisfactoraantagonismimprovesvasodilationduringhyperinsulinemiainmetabolicsyndrome
AT melinadomenico tumornecrosisfactoraantagonismimprovesvasodilationduringhyperinsulinemiainmetabolicsyndrome
AT moresnadia tumornecrosisfactoraantagonismimprovesvasodilationduringhyperinsulinemiainmetabolicsyndrome
AT bariniangela tumornecrosisfactoraantagonismimprovesvasodilationduringhyperinsulinemiainmetabolicsyndrome
AT mettimanomarco tumornecrosisfactoraantagonismimprovesvasodilationduringhyperinsulinemiainmetabolicsyndrome
AT laurodavide tumornecrosisfactoraantagonismimprovesvasodilationduringhyperinsulinemiainmetabolicsyndrome
AT iantornomicaela tumornecrosisfactoraantagonismimprovesvasodilationduringhyperinsulinemiainmetabolicsyndrome
AT quonmichaelj tumornecrosisfactoraantagonismimprovesvasodilationduringhyperinsulinemiainmetabolicsyndrome
AT cardillocarmine tumornecrosisfactoraantagonismimprovesvasodilationduringhyperinsulinemiainmetabolicsyndrome